Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPain Managementorthonet ReActiv8 coverage update | OpenPayer
    Ask Trek AI about this page
    CurrentorthonetPolicy N/A

    ReActiv8 Implantable Neurostimulation System — Coverage Criteria

    Customize your policy alerts

    Sign up for all orthonet policy alerts

    Know when orthonet releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Defines OrthoNet's coverage stance and evidence assessment for the ReActiv8 restorative neurostimulation system used to treat chronic mechanical low back pain associated with multifidus muscle dysfunction; applies to medical necessity determinations for members receiving this device.

    Policy Summary
    Payerorthonet
    PolicyReActiv8 Implantable Neurostimulation System — Coverage Criteria
    Policy CodePolicy N/A
    Change TypeTechnical — no material change
    Effective DateJun 4, 2026
    Last ReviewJun 4, 2026
    Next Review DateN/A
    Key ActionObtain and document imaging or physiological confirmation of multifidus dysfunction and prior failure of optimal medical management before requesting coverage.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    Not medically necessarycoverage stance
    PMA P190021FDA status
    RCTs & cohortsevidence
    CPTs listedcoding examples

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Coverage and Medical Necessity

    Medical necessity determination

    Covered when ALL of the following are met

    Policy coverage criteria: ReActiv8 is considered unproven and not medically necessary for chronic mechanical low back pain due to lumbar multifidus dysfunction because evidence is insufficient to determine efficacy

    Policy stance: not medically necessary per OrthoNet

    The ReActiv8® Implantable Neurostimulation System is considered unproven and not medically necessary for the treatment of chronic mechanical low back pain associated with lumbar multifidus muscle dysfunction. This policy stance reflects the determination that the device has not been shown to provide sufficient clinical benefit to meet OrthoNet coverage criteria for medical necessity.

    ReActiv8 is not medically necessary because there is insufficient evidence demonstrating improvement in net health outcomes for patients with chronic mechanical low back pain due to multifidus dysfunction. The available evidence does not adequately establish the therapy’s efficacy to support coverage.

    Prior Conservative Therapy Required

    Failure of prior conservative therapy (medications and physical therapy)

    Prior to consideration of ReActiv8, the following conservative therapy requirements must be documented. Covered when ALL of the following are met:

    Conservative therapy prerequisite: Patient has failed optimal medical management including pain medications and physical therapy before consideration of ReActiv8

    Per device indication and policy; documentation of failure of prior conservative therapy required

    Documentation of multifidus dysfunction: Clinical documentation confirming multifidus muscle dysfunction (e.g., positive prone instability test) and supporting imaging or physiological testing (e.g., lumbar MRI or physiological confirmation) is provided

    Imaging/physiological confirmation required to support patient selection

    Surgical candidacy: Documentation that the patient is not a candidate for spine surgery

    Provider must document reasons patient is not a surgical candidate

    Prior authorization and coding: Prior authorization is requested for the referenced CPT procedure codes when applicable (e.g., 64555, 64590, 76000, 64585, 64595, 95970, 95971, 95972) per payer rules

    Listing of CPT codes is for reference; coverage determined by member benefit and clinical necessity; prior authorization required per payer policies

    Step Therapy

    Conservative therapy prerequisite — failed optimal medical management and non‑surgical candidacy required

    Per the device indication, patients must have failed optimal medical management — including pain medications and physical therapy — prior to consideration of ReActiv8. The patient also must be not a candidate for spine surgery as part of selection for the device.

    • Failure of optimal medical management (including pain medications and physical therapy) is required.
    • Patient must not be a candidate for spine surgery.

    Documentation, Authorization, and Denial Guidance

    Prior Authorization

    Obtain prior authorization for referenced CPTs

    Prior authorization is required per payer policies when seeking coverage for implantation, generator insertion, fluoroscopy, revision/removal, and programming/analysis CPT services referenced by the manufacturer.

    • Example CPT codes listed for reference: 64555, 64590, 76000, 64585, 64595, 95970, 95971, 95972.
    • Coverage and prior authorization determined by member benefits and clinical necessity.
    Documentation Required

    Document multifidus dysfunction with clinical exam and testing

    Document clinical evidence of multifidus dysfunction (for example, a positive prone instability test) and include imaging or physiological testing that confirms the dysfunction.

    • Clinical exam findings (e.g., positive prone instability test).

    Procedure and Billing Codes

    Procedure codes referenced by manufacturerCPT
    64555Percutaneous implantation of neurostimulator electrode array; peripheral nerve (excludes sacral nerve).
    64590Insertion or replacement of peripheral or gastric neurostimulator pulse generator or receiver, direct or inductive coupling.
    76000Fluoroscopy, up to one hour- professional component.
    64585Revision or removal of peripheral neurostimulator electrode array.
    64595Revision or removal of peripheral or gastric neurostimulator pulse generator or receiver.
    95970Analysis.
    95971Analysis w/simple programming.
    95972Analysis w/complex programming.
    Therapy sessions — usage pattern (inv-05)
    Prescribed daily useTwo 30-minute stimulation sessions daily
    Session purposeRestore multifidus motor control and muscle function
    Patient population for sessionsAdults with chronic mechanical low back pain associated with multifidus dysfunction who have failed therapy and are not candidates for spine surgery
    Confirmation required before therapyClinical exam (e.g., positive prone instability test) and low back imaging (e.g., MRI) or physiological testing confirming multifidus dysfunction

    Imaging / Physiological Confirmation

    Note

    Require imaging/physiological confirmation for patient selection

    Patient selection requires imaging or physiological confirmation of multifidus muscle dysfunction to support consideration of the device.

    • Confirmatory evidence may include low back MRI or physiological testing demonstrating multifidus dysfunction.
    • Clinical exam (e.g., positive prone instability test) should corroborate imaging/physiological findings.

    Procedure Frequency and Related Notes

    Fluoroscopy (code 76000) referenced for implantation procedures (inv-14)
    Referenced CPT code76000 — Fluoroscopy, up to one hour; professional component
    Context of useReferenced by manufacturer for implantation procedures (device placement guidance)
    Coding noteListing of the code is for reference and does not imply coverage — coverage determined by member benefit document

    Key Definitions

    Multifidus muscle dysfunction — definition and diagnostic clues (inv-11)
    DefinitionClinical state in which dysfunction of the lumbar multifidus causes muscle weakness and spinal instability
    Diagnostic cluesPositive prone instability test on clinical examination
    Confirmatory testingLow back imaging (e.g., MRI) or physiological testing demonstrating multifidus dysfunction
    Clinical significanceAssociated with chronic mechanical low back pain in patients who have failed optimal medical management
    ReActiv8 system — device description (inv-12)
    Device componentsImplanted pulse generator, two stimulation leads, four electrodes, and a handheld battery-operated patient activator

    Device Background and Evidence Overview

    The ReActiv8® restorative neurostimulation system is an implanted device intended to restore motor control of the lumbar multifidus muscles by delivering scheduled stimulation sessions. It is designed for adults with chronic mechanical low back pain associated with multifidus dysfunction who have failed other therapies and are not candidates for spine surgery; the system delivers two 30‑minute daily stimulation sessions and targets motor branches of the dorsal ramus to elicit multifidus muscle activation.

    Items Not Covered

    The ReActiv8 system for chronic mechanical low back pain associated with multifidus dysfunction is not covered. It is considered unproven and not medically necessary due to insufficient evidence of benefit, and requests for this device will be denied on that basis.

    Policy Summary
    Payerorthonet
    PolicyReActiv8 Implantable Neurostimulation System — Coverage Criteria
    Policy CodePolicy N/A
    Change TypeTechnical — no material change
    Effective DateJun 4, 2026
    Last ReviewJun 4, 2026
    Next Review DateN/A
    Key ActionObtain and document imaging or physiological confirmation of multifidus dysfunction and prior failure of optimal medical management before requesting coverage.
    SourceLink
    On This Page
    Coverage and Medical NecessityPrior Conservative Therapy RequiredDocumentation, Authorization, and Denial GuidanceProcedure and Billing CodesImaging / Physiological ConfirmationProcedure Frequency and Related NotesKey DefinitionsDevice Background and Evidence OverviewItems Not Covered
    Policy coverage stance: ReActiv8 is considered unproven and not medically necessary due to insufficient evidence to determine efficacy; requests may be denied as not medically necessary

    Policy stance: not medically necessary per OrthoNet

  1. Low back imaging (e.g., MRI) or physiological testing confirming multifidus muscle dysfunction.
  2. Denial Risk

    Denial risk — device considered unproven

    Requests for ReActiv8 will be denied as not medically necessary because the policy considers the device unproven with insufficient evidence to demonstrate improvement in net health outcomes.

    • Policy statement: ReActiv8 is considered unproven and not medically necessary for chronic mechanical low back pain due to multifidus dysfunction.
    Stimulation targetBilateral stimulation of the L2 medial branch of the dorsal ramus (as it crosses the transverse process at L3)
    Therapy goalRestore multifidus motor control and muscle function
    Regulatory statusFDA premarket approval (PMA P190021, June 2020)